Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced second interim top-line overall survival (OS)

HERIZON-GEA-01 results reinforce recently FDA-approved Ziihera as the definitive HER2-targeted backb

Jazz Pharmaceuticals (NASDAQ: JAZZ) outlined its plans for the U.S. launch of Ziihera following FDA

DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals

Deutsche Bank analyst David Hoang maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and rai

Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its mark

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweigh

The U.S. Food and Drug Administration (FDA), on Tuesday, approved Jazz Pharmaceuticals plc's (NASDAQ

FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy a

Top analysts changed outlook on top names: Piper raised $INTU price target, Ascendiant raised $QUBT

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz In

DUBLIN, Aug. 26, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the

Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Li

Jazz Pharmaceuticals NASDAQ: JAZZ outlined its plans for the U.S. launch of Ziihera following FDA ap

AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the com

FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positiv

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (F

Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patien

Jazz Pharmaceuticals acquires Actio Biosciences for $820 million upfront, targeting rare KCNT1+ epil

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweigh

Jazz Pharmaceuticals will acquire Actio Biosciences, Inc. for $820 million. Deal centers around Acti

Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's foreca

Jazz Pharmaceuticals said on Monday it would buy privately held Actio Biosciences in a deal valued a

Actio Biosciences' lead clinical asset is ABS-1230, a novel, first-in-class small molecule preci

Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leve

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both

Jazz Pharmaceuticals has delivered strong year-to-date performance, raising full-year revenue guidan

Bank of America Corp DE grew its position in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 10.9% in the

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported second-quarter 2026 revenue of $1.21 billion, up 16% fr

Amundi raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 2,445.3% in the first quart

JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy a

TD Cowen analyst Joseph Thome maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises

Wells Fargo analyst Mohit Bansal maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight a

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweigh

Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweig

Jazz Pharmaceuticals (JAZZ) reported Q2 sales above estimates and raised its FY26 sales guidance. A

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and

Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and rais

Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2026 sales outlook from $4.250 billion-$4.500 billion to

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $5.71 per share which missed the a

Wall Street analysts change ratings for FITB, TRVI, JAZZ, GPN, EAT, URBN, MNST. See full list on ben

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the

Wall Street analysts change outlook on top stocks. For detailed ratings, upgrades/downgrades, see an

Canaccord Genuity analyst Gary Nachman initiates coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ) w

Summary: Wall Street analysts changed rating for JAZZ, AFRM, MNDY, NGEN, FCEL, RRR, ABNB, KARO. See